Inhaled Nitric Oxide Market Analysis North America, APAC, Europe, South America, Middle East and Africa - US, China, India, Germany, UK - Size and Forecast 2024-2028

Inhaled Nitric Oxide Market Size 2024-2028 

The inhaled nitric oxide market size is estimated to grow by USD 462.5 million at a CAGR of 10.77% between 2023 and 2028. The market is experiencing significant growth due to its increasing utilization in various medical applications, particularly in cardiac surgeries. The use of inhaled nitric oxide during surgeries helps maintain adequate blood flow to vital organs, reducing the risk of complications. Additionally, the rising number of patients diagnosed with chronic obstructive pulmonary disease (COPD) is fueling market growth, as inhaled nitric oxide is an effective treatment for improving pulmonary function. However, the market faces challenges due to the potential adverse effects of inhaled nitric oxide, including methemoglobinemia and increased risk of infections. Despite these challenges, the market is expected to continue growing due to its proven clinical benefits and the development of advanced delivery systems to mitigate side effects.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

Inhaled nitric oxide is a colorless, odorless gas used primarily in medical treatments for various respiratory conditions. Its primary use is in the neonatal population, particularly for preterm births, to prevent and treat respiratory complications such as respiratory distress syndrome. Inhaled nitric oxide possesses vasodilatory properties, making it an effective pulmonary vasodilator for pulmonary hypertension and oxygenation in cases of ventilation-perfusion mismatch and high pulmonary vascular resistance. Beyond neonatal applications, inhaled nitric oxide is also used to treat respiratory disorders in adults, including persistent pulmonary hypertension and asthma. Additionally, it has antimicrobial properties and is used by athletes and fitness enthusiasts for performance enhancement. Inhaled nitric oxide is typically administered using a mixture of nitrogen, argon, hydrogen, or carbon monoxide as a carrier gas. While oxygen is often used in conjunction with nitric oxide therapy, excessive exposure can lead to potential risks, including methemoglobinemia. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

Use of inhaled nitric oxide in cardiac surgeries is notably driving market growth. Inhaled nitric oxide (iNO) is a vital gas with significant applications in the treatment of both respiratory and cardiovascular diseases. iNO functions as a selective pulmonary vasodilator, improving pulmonary hemodynamics in various clinical conditions, such as life-threatening right ventricular dysfunction and failure. Its therapeutic use extends to treating hypoxemic respiratory failure and supporting systemic blood pressure during cardiothoracic surgeries.

Furthermore, iNO administration techniques include various delivery systems, such as gas-filled balloons, metered-dose inhalers, and ventilator circuits. Regulatory guidelines and pricing and reimbursement policies play crucial roles in determining the healthcare expenditure associated with iNO therapy. Despite its clinical benefits, the high cost of iNO therapy and the complex administration techniques remain challenges to its widespread adoption. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

Rise in the number of patients with COPD is the key trend in the market. Chronic obstructive pulmonary disease (COPD) is a non-communicable condition that significantly impacts the respiratory system, leading to persistent obstruction of airflow from the lungs. This disease is primarily caused by lifestyle factors, such as smoking and exposure to biomass fuels and air pollution. According to the World Health Organization (WHO), COPD is the third-leading cause of death worldwide, with smoking being the primary risk factor, particularly in developed countries like the US. The administration of nitric oxide (NO) through inhalation has emerged as an effective therapeutic approach for managing COPD and certain cardiovascular diseases.

Furthermore, delivery systems and administration techniques for NO have advanced significantly, enabling more precise and controlled dosing. Regulatory guidelines, including the US Food and Drug Administration (FDA), have approved the use of inhaled NO for specific indications. Despite the proven benefits, the high cost of inhaled NO and the complexities of its delivery systems pose challenges to its widespread adoption. Pricing and reimbursement policies, as well as healthcare expenditure, are critical factors influencing the market growth of inhaled NO. The global market is anticipated to grow steadily, driven by increasing disease prevalence, technological advancements, and regulatory approvals. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

Adverse effects of inhaled nitric oxide is the major challenge that affects the growth of the market. Inhaled nitric oxide (iNO) is a therapeutic gas utilized primarily in the treatment of respiratory and cardiovascular diseases. Its pharmacological properties, including the relaxation of bronchial smooth muscles and improvement of pulmonary blood flow, are attributed to increased cellular cyclic guanosine monophosphate (cGMP) levels. However, the same mechanism might hinder regular cellular proliferation and lead to toxicological effects.

Furthermore, iNO can also result in mutagenic deoxyribonucleic acid (DNA) base changes or strand breakage. Moreover, nitric oxide can react with oxygen in the lungs to form nitrogen dioxide, a potent lung irritant. The interaction between nitric oxide and superoxide anion can lead to the generation of peroxynitrite, a cytotoxic oxidant that negatively impacts surfactant performance. Delivery systems and administration techniques for iNO are crucial in mitigating these toxicological effects. Regulatory guidelines, pricing, and reimbursement policies, as well as healthcare expenditure, significantly influence the market growth. Hence, the above factors will impede the growth of the market during the forecast period

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Beyond Air Inc - The company offers inhaled nitric oxide using LungFit, a system that may be used anywhere in the hospital setting, providing the opportunity to treat infants with pulmonary hypertension and bronchiolitis.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Air Liquide SA
• Berkeley Life and L2G North America Inc.
• Beyond Air Inc
• Geno Pharmaceuticals Pvt. Ltd.
• Getinge AB
• Halma Plc
• HumanN
• Inspiration Healthcare Group Plc.
• Linde Plc
• Mallinckrodt Plc
• Merck KGaA
• Moda Health Plan Inc.
• NIOX Group plc
• SOL India Pvt Ltd
• The Cigna Group
• Uniscience Group
• VERO Biotech

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

By Application 

The Neonatal respiratory treatment segment is estimated to witness significant growth during the forecast period. The global market is witnessing significant growth, particularly in the neonatal segment. Neonatal respiratory disorders, including respiratory distress syndrome (RDS) and hypoxic respiratory failure (HRF), are common in preterm infants, leading to an increased demand for inhaled nitric oxide. This gas possesses vasodilatory properties, making it an effective pulmonary vasodilator for treating neonatal pulmonary hypertension, a condition characterized by increased pulmonary vascular resistance and hypertension.

Get a glance at the market share of various regions Download the PDF Sample

The Neonatal respiratory treatment segment was the largest segment and was valued at USD 216.80 million in 2018. Inhaled nitric oxide therapy enhances oxygenation in infants with this condition, thereby improving their overall health. Moreover, inhaled nitric oxide exhibits anti-inflammatory properties, making it beneficial in managing respiratory disorders, such as asthma, in the geriatric population. In addition, inhaled nitric oxide is used in the treatment of cardio-cerebrovascular disorders, including coronavirus disease (COVID-19) and its strains, due to its cardiovascular protective effects. The pharmaceuticals industry is a significant contributor to the market's growth, as healthcare providers increasingly recognize the financial burden of respiratory and cardiovascular disorders and seek cost-effective treatment options. However, regulatory hurdles and the need for specialized equipment, such as extracorporeal membrane oxygenation, pose challenges to the market's growth. Inhaled nitric oxide is typically administered as a gas mixture with nitrogen, argon, hydrogen, or oxygen, and its production involves complex processes. The gas segment holds a significant share of the market due to the increasing demand for inhaled nitric oxide in various therapeutic applications. Overall, the market for inhaled nitric oxide is expected to continue growing due to its potential to treat a wide range of respiratory and cardiovascular disorders.

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 30% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Inhaled nitric oxide is a vital medical gas utilized primarily in neonatal care for the treatment of respiratory complications, including respiratory distress syndrome and hypoxic respiratory failure. Its vasodilatory properties help reduce pulmonary vascular resistance and pulmonary hypertension, improving oxygenation and ventilation-perfusion matching. Inhaled nitric oxide is also used in adults, particularly those with cardiovascular disorders, such as persistent pulmonary hypertension, cardio-cerebrovascular disorders, and coronavirus disease strains. Its anti-inflammatory properties make it beneficial in various respiratory disorders. Healthcare providers increasingly rely on this pulmonary vasodilator to manage hypoxemic respiratory failure and ventilation-perfusion mismatch. However, the financial burden and regulatory hurdles associated with its use may limit its widespread adoption. The gas segment of the medical technology industry includes nitric oxide, along with nitrogen, argon, hydrogen, carbon monoxide, and oxygen. The pharmaceuticals industry also explores nitric oxide's antimicrobial properties and its potential use in treating asthma and other conditions. Inhaled nitric oxide's applications extend beyond healthcare, with athletes and fitness enthusiasts using it for performance enhancement.

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Application Outlook
  • Neonatal respiratory treatment
  • Chronic obstructive pulmonary disease (COPD)
  • Acute respiratory distress syndrome (ARDS)
  • Others

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • South America
    • Chile 
    • Brazil 
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

You may also interested in the below market reports

• Acute Respiratory Distress Syndrome Treatment Market: Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast

• Pulmonary Arterial Hypertension (Pah) Drugs Market: Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, Canada, Japan - Size and Forecast

• Nitric Acid Market: by Application, Grade Type, and Geography - Forecast and Analysis

Market Analyst Overview

Inhaled nitric oxide is a vasodilator and antioxidant gas used primarily in healthcare settings for the treatment of various respiratory and cardiovascular disorders. Its primary indications include preterm birth-related complications such as respiratory distress syndrome (RDS) and hypoxic respiratory failure in neonates. Inhaled nitric oxide's pulmonary vasodilator properties help improve oxygenation and reduce pulmonary vascular resistance in conditions like pulmonary hypertension and hypoxemic respiratory failure. Besides respiratory disorders, inhaled nitric oxide is also used in the treatment of cardiovascular disorders like angina and myocardial infarction due to its vasodilatory and anti-inflammatory properties. Preterm birth can lead to complications such as neonatal hypoxic respiratory failure, particularly in infants with underlying chronic obstructive pulmonary diseases. The geriatric population and individuals with asthma, coronavirus disease, and coronavirus strains also benefit from inhaled nitric oxide therapy. The market is driven by the increasing prevalence of respiratory and cardiovascular disorders, growing awareness among healthcare providers, and the financial burden of these conditions on patients and healthcare systems.

However, regulatory hurdles and the high cost of production and delivery of inhaled nitric oxide pose challenges to the market growth. The market comprises the gas segment, which includes nitric oxide, nitrogen, argon, hydrogen, carbon monoxide, and oxygen. The pharmaceuticals industry plays a significant role in the production and distribution of inhaled nitric oxide. Inhaled nitric oxide's antimicrobial properties and potential use in fitness enthusiasts and athletes are emerging areas of research. Overall, the market is expected to grow steadily due to its diverse therapeutic applications and the increasing demand for effective treatments for respiratory and cardiovascular disorders.

Download PDF Sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies